Short Bowel Syndrome Market Research Report present a detailed analysis of the market listing, Drug therapies and pipeline for study period from 2018-2030

Short Bowel Syndrome Market Size, Share | Short Bowel Syndrome Market Research Report, Market Analysis, Market Growth, trends and Forecast

DelveInsight&rsquo;s &lsquo;Short Bowel Syndrome&ndash;Market Insights, Epidemiology, and Market Forecast&mdash;2030&rsquo; report deliver an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Short Bowel Syndrome market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Short Bowel Syndrome symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Short Bowel Syndrome symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
<h2>Geography Covered</h2>
<ul>
<li>The United States</li>
<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
<li>Japan</li>
</ul>
Study Period: 2018&ndash;2030
<h2>Short Bowel Syndrome Disease Understanding and Treatment Algorithm</h2>
Short Bowel Syndrome Overview
Short Bowel Syndrome is a congenital or acquired condition affecting the small intestine, hallmarked by loss of intestinal absorptive capacity with resultant malabsorption, dehydration, and malnutrition. This is due to the loss of absorptive surface area, as the human intestinal tract requires a massive surface area to absorb nutrients to support a growing and living organism effectively.
&nbsp;
Short Bowel Syndrome is a challenging condition associated with significant morbidity and mortality, reduced quality of life, and high health care costs. In patients with Short Bowel Syndrome who are receiving long-term home parenteral nutrition (PN), 2&ndash;5 years survival rates have been reported to be up to 80% and 70%, respectively. Factors affecting survival with Short Bowel Syndrome include the anatomy and function of the remaining bowel, the patient's age, the primary disease process, comorbid diseases, the presence of chronic intestinal obstruction, and the experience of the management team.
&nbsp;
Most commonly, Short Bowel Syndrome develops after surgical removal of a portion of the small intestine. This surgery is done to treat different types of intestinal conditions, like being born with a narrowed small intestine, or missing a portion of this part of the digestive system (intestinal atresia), injury to the intestines from physical trauma, sluggish movement within the intestines, cancer or cancer treatment that impacts the intestines, scarring of the intestines due to Crohn&rsquo;s disease, causing obstruction in the digestive tract, and loss of blood flow to the intestines as a result of blood vessel blockage.
&nbsp;
The main symptom of Short Bowel Syndrome is diarrhea&mdash;loose, watery stools. Diarrhea can lead to dehydration, malnutrition, and weight loss. Dehydration means the body lacks enough fluid and electrolytes&mdash;chemicals in salts, including sodium, potassium, and chloride&mdash;to work properly. Malnutrition is a condition that develops when the body does not get the right amount of vitamins, minerals, and nutrients it needs to maintain healthy tissues and organ function. Loose stools contain more fluid and electrolytes than solid stools. These problems can be severe and can be life-threatening without proper treatment.
&nbsp;
Short Bowel Syndrome Diagnosis and Treatment 
It covers the details of conventional and current medical therapies and diagnosis available in the Short Bowel Syndrome market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
&nbsp;
The DelveInsight Short Bowel Syndrome market report gives a thorough understanding of Short Bowel Syndrome symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Short Bowel Syndrome symptoms of treatment algorithms and treatment guidelines for Short Bowel Syndrome symptoms in the US, Europe, and Japan.
<h2>Short Bowel Syndrome Epidemiology</h2>
The epidemiology division&rsquo;s Short Bowel Syndrome symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
&nbsp;
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Short Bowel Syndrome&nbsp;epidemiology segmented as the Prevalent Cases of Short Bowel Syndrome, Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF), Age-specific Cases of Short Bowel Syndrome, Gender-specific Cases of Short Bowel Syndrome, Etiology-specific Cases. The report includes the prevalent Short Bowel Syndrome scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
<h2>Country Wise- Short Bowel Syndrome Epidemiology</h2>
The epidemiology segment also provides the Short Bowel Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
&nbsp;
The total 7MM prevalent cases of Short Bowel Syndrome were 34,713 cases in 2020.
<h2>Short Bowel Syndrome Drug Chapters</h2>
The drug chapter segment of the Short Bowel Syndrome report encloses the detailed analysis of Short Bowel Syndrome marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Short Bowel Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
&nbsp;
Management of short bowel syndrome requires a multi-disciplinary approach that includes neonatologists, gastroenterologists, surgeons, nutritionists, pharmacists, nurses, and social workers. Guidelines have been set forth regarding the optimal Short Bowel Syndrome classification and management, but they must be taken in the context of the situation and cannot be used in every circumstance. Treatment includes Parenteral Nutrition and Enteral Nutrition and usually involves medications to help ease your signs and symptoms and increase the absorption rate.
Products detail in the report&hellip;
&nbsp;
Short Bowel Syndrome Emerging Drugs 
Glepaglutide is also known as ZP 1848&mdash;a long-acting glucagon-like peptide-2 (GLP-2) analog that was developed for patients with reduced or complete loss of intestinal function. Many people with Short Bowel Syndrome are dependent on the frequent intake of intravenous fluids and nutrition delivered through a central catheter. Currently, Glepaglutide is participating in Phase III clinical trial to determine the safety and efficacy of subcutaneous injection of the drug for the treatment of Short Bowel Syndrome.
Products detail in the report&hellip;
<h2>Short Bowel Syndrome Market Outlook</h2>
The Short Bowel Syndrome market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Short Bowel Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
&nbsp;
This segment gives a thorough detail of Short Bowel Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria&rsquo;s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
&nbsp;
According to DelveInsight, Short Bowel Syndrome market in 7MM is expected to change in the study period 2018&ndash;2030.
&nbsp;
Key Findings
This section includes a glimpse of the Short Bowel Syndrome market in 7MM. The market size of Short Bowel Syndrome in the seven major markets was USD 1720.5 million in 2020, and the market is estimated to increase at a CAGR of 5.82% for the study period (2018&ndash;2030).
&nbsp;
The United States Market Outlook
This section provides a total of Short Bowel Syndrome market size and market size by therapies in the United States.
&nbsp;
The United States accounts for the largest Short Bowel Syndrome market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
&nbsp;
EU-5 Countries: Market Outlook
The total Short Bowel Syndrome market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
&nbsp;
Japan Market Outlook 
The total Short Bowel Syndrome market size and market size by therapies in Japan are also mentioned.
<h2>Short Bowel Syndrome Drugs Uptake</h2>
This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018&ndash;2030. The analysis covers Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and drug sales.
&nbsp;
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.
<h2>Short Bowel Syndrome Pipeline Development Activities</h2>
The report provides insights into different therapeutic candidates in the Phase II and Phase III stage. It also analyses Short Bowel Syndrome key players involved in developing targeted therapeutics.
&nbsp;
Major players include Glepaglutide (Zealand Pharma), Apraglutide (VectivBio AG), and NM 002 (9 Meters Biopharma), being assessed as potential therapies to be available in the market in the coming future.
&nbsp;
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Short Bowel Syndrome emerging therapies.
<h2>KOL Views</h2>
To keep up with current market trends, we take KOLs and SME&rsquo;s opinion working in the Short Bowel Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Short Bowel Syndrome market trends. This will support the clients in potential upcoming novel treatment by identifying the market&rsquo;s overall scenario and the unmet needs.
<h2>Competitive Intelligence Analysis</h2>
We perform a Competitive and Market Intelligence analysis of the Short Bowel Syndrome Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
<h2>Scope of the Report</h2>
<ul>
<li>The report covers the descriptive overview of Short Bowel Syndrome, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies</li>
<li>Comprehensive insight has been provided into the Short Bowel Syndrome epidemiology and treatment in the 7MM</li>
<li>Additionally, an all-inclusive account of both the current and emerging therapies Short Bowel Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape</li>
<li>A detailed review of Short Bowel Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM</li>
<li>The report provides an edge while developing business strategies by understanding trends shaping and driving the global Short Bowel Syndrome market</li>
</ul>
<h2>Report Highlights</h2>
<ul>
<li>In the coming years, Short Bowel Syndrome market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market</li>
<li>The companies and academics are working to assess challenges and seek opportunities that could influence Short Bowel Syndrome R&amp;D. The therapies under development are focused on novel approaches to treat/improve the disease condition</li>
<li>Major players are involved in developing therapies for Short Bowel Syndrome. The launch of emerging therapies will significantly impact the Short Bowel Syndrome market</li>
<li>A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Short Bowel Syndrome.</li>
<li>Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities</li>
</ul>
<h2>Short Bowel Syndrome Report Insights</h2>
<ul>
<li>Patient Population</li>
<li>Therapeutic Approaches</li>
<li>Short Bowel Syndrome Pipeline Analysis</li>
<li>Short Bowel Syndrome Market Size and Trends</li>
<li>Market Opportunities</li>
<li>Impact of upcoming therapies</li>
</ul>
<h2>Short Bowel Syndrome Report Key Strengths</h2>
<ul>
<li>10 years Forecast</li>
<li>7MM Coverage</li>
<li>Short Bowel Syndrome Epidemiology Segmentation</li>
<li>Key Cross Competition</li>
<li>Highly Analyzed Market</li>
<li>Drugs Uptake</li>
</ul>
<h2>Short Bowel Syndrome Report Assessment</h2>
<ul>
<li>Current Treatment Practices</li>
<li>Unmet Needs</li>
<li>Pipeline Product Profiles</li>
<li>Market Attractiveness</li>
<li>Market Drivers and Barriers</li>
</ul>
<h2>Key Questions</h2>
Market Insights:
<ul>
<li>What was the Short Bowel Syndrome Market share (%) distribution in 2020, and how would it look in 2030?</li>
<li>What would be the Short Bowel Syndrome total market Size as well as market Size by therapies across the 7MM during the forecast period (2021&ndash;2030)?</li>
<li>What are the market&rsquo;s key findings across 7MM, and which country will have the largest Short Bowel Syndrome market Size during the forecast period (2021&ndash;2030)?</li>
<li>At what CAGR, the Short Bowel Syndrome market is expected to grow by 7MM during the forecast period (2021&ndash;2030)?</li>
<li>What would be the Short Bowel Syndrome market outlook across the 7MM during the forecast period (2021&ndash;2030)?</li>
<li>What would be the Short Bowel Syndrome market growth till 2030, and what will be the resultant market Size in the year 2030?</li>
<li>How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?</li>
</ul>
&nbsp;
Epidemiology Insights:
<ul>
<li>What are the disease risk, burden, and unmet needs of Short Bowel Syndrome?</li>
<li>What is the historical Short Bowel Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>What would be the forecasted patient pool of Short Bowel Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>What will be the growth opportunities in the 7MM concerning the patient population about Short Bowel Syndrome?</li>
<li>Out of all 7MM countries, which country would have the highest prevalent Short Bowel Syndrome population during the forecast period (2021&ndash;2030)?</li>
<li>At what CAGR is the population expected to grow by 7MM during the forecast period (2021&ndash;2030)?</li>
</ul>
&nbsp;
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
<ul>
<li>What are the current options for the treatment of Short Bowel Syndrome?</li>
<li>What are the current treatment guidelines for treating Short Bowel Syndrome in the USA, Europe, and Japan?</li>
<li>What are the Short Bowel Syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?</li>
<li>How many companies are developing therapies for the treatment of Short Bowel Syndrome?</li>
<li>How many therapies are developed by each company for the treatment of Short Bowel Syndrome?</li>
<li>How many emerging therapies are in the mid-stage and late development stages to treat Short Bowel Syndrome?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Short Bowel Syndrome therapies?</li>
<li>What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for Short Bowel Syndrome and their status?</li>
<li>What are the key designations that have been granted for the emerging therapies for Short Bowel Syndrome?</li>
<li>What are the global historical and forecasted markets of Short Bowel Syndrome?</li>
</ul>
<h2>Reasons to buy</h2>
<ul>
<li>The report will help in developing business strategies by understanding trends shaping and driving the Short Bowel Syndrome market</li>
<li>To understand the future market competition in the Short Bowel Syndrome market and Insightful review of the key market drivers and barriers</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for Short Bowel Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan</li>
<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for the Short Bowel Syndrome market</li>
<li>To understand the future market competition in the Short Bowel Syndrome market</li>
</ul>

1. Key Insights
2. Report Introduction
3. Short bowel syndrome Market Overview at a Glance
3.1. Market Share (%) Distribution of Short bowel syndrome in 2018
3.2. Market Share (%) Distribution of Short bowel syndrome in 2030
4. Executive Summary of Short Bowel Syndrome
5. Disease Background and Overview
5.1. Introduction
5.2. Causes
5.3. Symptoms
5.4. Clinical Features and Effect of Malabsorption
5.5. Complications of Short Bowel Syndrome
5.6. Diagnosis
5.7. Clinical Presentation of Infants with Short Bowel Syndrome
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Prevalent Patient Population of Short Bowel Syndrome
7. Epidemiology of Short Bowel Syndrome
7.1. The United States
7.1.1. Prevalent Cases of Short Bowel Syndrome in the United States
7.1.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in the United States
7.1.3. Age-specific Cases of Short Bowel Syndrome in the United States
7.1.4. Gender-specific Cases of Short Bowel Syndrome in the United States
7.1.5. Etiology-specific Cases in the United States
7.2. EU5
7.3. Germany
7.3.1. Prevalent Cases of Short Bowel Syndrome in Germany
7.3.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in Germany
7.3.3. Age-specific Cases of Short Bowel Syndrome in Germany
7.3.4. Gender-specific Cases of Short Bowel Syndrome in Germany
7.3.5. Etiology-specific Cases in Germany
7.4. France
7.4.1. Prevalent Cases of Short Bowel Syndrome in France
7.4.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in France
7.4.3. Age-specific Cases of Short Bowel Syndrome in France
7.4.4. Gender-specific Cases of Short Bowel Syndrome in France
7.4.5. Etiology-specific Cases in France
7.5. Italy
7.5.1. Prevalent Cases of Short Bowel Syndrome in Italy
7.5.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in Italy
7.5.3. Age-specific Cases of Short Bowel Syndrome in Italy
7.5.4. Gender-specific Cases of Short Bowel Syndrome in Italy
7.5.5. Etiology-specific Cases in Italy
7.6. Spain
7.6.1. Prevalent Cases of Short Bowel Syndrome in Spain
7.6.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in Spain
7.6.3. Age-specific Cases of Short Bowel Syndrome in Spain
7.6.4. Gender-specific Cases of Short Bowel Syndrome in Spain
7.6.5. Etiology-specific Cases in Spain
7.7. UK
7.7.1. Prevalent Cases of Short Bowel Syndrome in UK
7.7.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in UK
7.7.3. Age-specific Cases of Short Bowel Syndrome in UK
7.7.4. Gender-specific Cases of Short Bowel Syndrome in UK
7.7.5. Etiology-specific Cases in UK
7.8. Japan
7.8.1. Prevalent Cases of Short Bowel Syndrome in Japan
7.8.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in Japan
7.8.3. Age-specific Cases of Short Bowel Syndrome in Japan
7.8.4. Gender-specific Cases of Short Bowel Syndrome in Japan
7.8.5. Etiology-specific Cases in Japan
8. Organizations contributing towards Short Bowel Syndrome
9. Patient Journey
10. Case Reports
11. Treatment of Short Bowel Syndrome
11.1. Management of short bowel syndrome
11.2. Pharmacological interventions in Short Bowel Syndrome
11.3. Surgical management of Short Bowel Syndrome
12. Marketed Products
12.1. Gattex: Takeda
12.1.1. Product Description
12.1.2. Regulatory Milestones
12.1.3. Safety and Efficacy
12.1.4. Product Profile
13. Emerging Products
13.1. Glepaglutide: Zealand Pharma
13.1.1. Drug Descriptions
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Clinical Trials Information
13.1.5. Safety and Efficacy
13.1.6. Product Profile
13.2. Apraglutide: VectivBio AG
13.2.1. Drug Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Clinical Trials Information
13.2.5. Product Profile
13.3. NM 002: 9 Meters Biopharma
13.3.1. Drug Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Clinical Trials Information
13.3.5. Safety and Efficacy
13.3.6. Product Profile
14. Short Bowel Syndrome: 7 Major Market Analysis
14.1. Key Findings
14.2. Market Size of Short Bowel Syndrome in 7MM
15. Market Outlook
15.1. United States Market Size
15.1.1. Total Market Size of Short bowel syndrome in United States
15.1.2. Market Size of Short bowel syndrome by Therapies in United States
15.2. EU-5 Market Size
15.3. Germany
15.3.1. Total Market size of Short bowel syndrome in Germany
15.3.2. Market Size of Short bowel syndrome by Therapies in Germany
15.4. France
15.4.1. Total Market size of Short bowel syndrome in France
15.4.2. Market Size of Short bowel syndrome by Therapies in France
15.5. Italy
15.5.1. Total Market size of Short bowel syndrome in Italy
15.5.2. Market Size of Short bowel syndrome by Therapies in Italy
15.6. Spain
15.6.1. Total Market size of Short bowel syndrome in Spain
15.6.2. Market Size of Short bowel syndrome by Therapies in Spain
15.7. United Kingdom
15.7.1. Total Market size of Short bowel syndrome in United Kingdom
15.7.2. Market Size of Short bowel syndrome by Therapies in United Kingdom
15.8. Japan
15.8.1. Total Market size of Short bowel syndrome in Japan
15.8.2. Market Size of Short bowel syndrome by Therapies in Japan
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Unmet Needs
20. Appendix
21. Bibliography
22. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight

Short Bowel Syndrome Market

Short Bowel Syndrome- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight' s Short Bowel Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides the detailed overview of the disease and in depth understanding..